ArticleStem cell research & therapy2026
Role of ASLNC168501 in regulating hair follicle stem cell activity via the AR/miR-128-3p/IGF-1 pathway.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHair follicle stem cells (HFSCs) in androgenetic alopecia (AGA) patients exhibit functional impairment, reduced quantity, dysregulation, and androgen sensitivity, which hinder therapeutic strategies targeting HFSCs activation for hair regeneration. This study aims to elucidate the molecular mechanisms underlying HFSCs dysfunction in AGA and identify novel therapeutic targets.
methodsWe compared the expression of insulin-like growth factor 1 (IGF-1) in hair follicle tissues between AGA patients and healthy controls, analyzing transcriptional and protein-level differences. Bioinformatics, luciferase assays, and correlation analyses were employed to investigate the AR/miR-128-3p/IGF-1 pathway. Mechanistic studies were conducted using dermal papilla cells (DPCs) from both AGA patients and normal donors, which included RNA interaction assays and functional validation. Furthermore, the mechanism was validated by assessing the phenotypic changes in HFSCs co-cultured experiments. In vivo experiments in AGA mice were performed to evaluate hair follicle regeneration following ASLNC168501 overexpression.
resultsIGF-1 expression was markedly reduced in hair follicles of AGA patients, with transcriptional alterations occurring later than changes at the protein-level alterations. Dysregulation of the AR/miR-128-3p/IGF-1 pathway in DPCs was identified as a key driver of HFSCs dysfunction: AR transcriptionally activates miR-128-3p, which in turn suppresses IGF-1 by binding to its 3'UTR. Consequently, the ability of IGF-1 to sustain and support HFSCs activity is impaired. The endogenous ASLNC168501 functions as a ceRNA, sequestering miR-128-3p and thereby restoring IGF-1 expression and secretion. Exogenous overexpression of ASLNC168501 in DPCs significantly promoted the self-renewal, proliferative and differentiation potential of co-cultured HFSCs in vitro and reversed hair follicle atrophy in AGA mice.
conclusionsOur findings demonstrate that loss of ASLNC168501 accelerates the progression of AGA by activating AR/miR-128-3p/IGF-1 pathway activation. Acting as a pathway-independent RNA, ASLNC168501 holds a target significant therapeutic potential for restoring HFSCs function and promoting hair follicle regeneration. This finding highlights a novel molecular target and contributes to the advancement of precision medicine strategies for androgen-related alopecia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.